@article {7906,
	title = {Management of Relapsed and Relapsed Refractory Myeloma},
	journal = {Hematology/Oncology Clinics of North America},
	volume = {21},
	year = {2007},
	note = {Cited By :10Export Date: 21 February 2017},
	month = {2007},
	pages = {1175 - 1215},
	abstract = {Studies of bortezomib, thalidomide, and lenalidomide have shown promising clinical activity in relapsed/refractory multiple myeloma (MM). Bortezomib alone and in combination with other agents is associated with high response rates, consistently high rates of complete response, and a predictable and manageable profile of adverse events. Thalidomide-based regimens have also shown substantial clinical activity. The accumulating experience from ongoing trials of bortezomib/lenalidomide/dexamethasone combinations in patients who have relapsed/refractory or newly diagnosed MM will provide critical information that will determine the possible role of this combination as the basic backbone for combination regimens for management of advanced MM. {\textcopyright} 2007 Elsevier Inc. All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-35748932956\&doi=10.1016\%2fj.hoc.2007.08.014\&partnerID=40\&md5=a670b539d2d4bc892480ca0207acbd82},
	author = {Kastritis, E. and Mitsiades, C.S. and Dimopoulos, M.A. and Richardson, P.G.}
}
